Today, chronic obstructive pulmonary disease is the third leading cause of death globally. Over the past ten years, the number of pharmaceutical medications available to treat COPD patients has increased. Patients with advanced COPD are especially vulnerable to negative outcomes and issues with medical treatment. According to guidelines, patients with moderate COPD should take a combination of bronchodilators, particularly muscarinic antagonist and B2-agonist, as well as B2-agonist and inhaled corticosteroid. Patients with severe COPD should take a combination of muscarinic antagonist, B2-agonist, and inhaled corticosteroid. Compared to either medication alone, they may exhibit additive and synergistic bronchodilation. To compare the course of the disease in patients undergoing dual bronchodilation with a LABA + LAMA as a fixed combination (dual bronchodilation) and those undergoing triple therapy of a LABA + LAMA & ICS, we have taken data for analysis in the current publication. We hypothesized that triple dosage therapy would be safer and more effective than dual bronchodilation.
Bhavya. D, 1* Thanuja B L1, Brahmini S V1, Shrunga R N1, Yasmeen Taj1 and Prof. Keerthi. N2 (Mon,) studied this question.